BioAdvance News Palvella Therapeutics Portfolio News

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

By WebmasterMarch 6, 2020November 1st, 2024No Comments

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita
Top-Line Data Expected in Q4 2020 for Fast Track-Designated Program

See more here

Previous PostRelmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development
Next PostRide Health CEO Imran Cronk to Present at South by Southwest Alongside Leaders from American Heart Association and Ascension

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostRelmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development

Next PostRide Health CEO Imran Cronk to Present at South by Southwest Alongside Leaders from American Heart Association and Ascension